HCV New Drugs

Drug Companies Tie Costs to Outcomes
By Peter Loftus
But early signs show little evidence that the plans lower prices
In one deal, Gilead Sciences Inc. agreed to pay Cigna additional rebates if its hepatitis C drug Harvoni cured less than 95% of Cigna’s patients who took it, he says. Cure rates have exceeded that threshold and Gilead hasn’t paid additional rebates beyond a base rebate that isn’t tied to the drug’s performance.

Continue reading....